From biobanking to personalized prevention of obesity, diabetes and metabolic syndrome

• Published in: Kardiovaskuli͡a︡rnai͡a︡ terapii͡a︡ i profilaktika Vol. 20; no. 8; p. 3123
• Main Authors: Ershova, A. I., Ivanova, A. A., Kiseleva, A. V., Sotnikova, E. A., Meshkov, A. N., Drapkina, O. M.
• Format: Journal Article
• Language: English; Russian
• Published: SILICEA-POLIGRAF» LLC 09.01.2022
• Subjects: gwas (genome-wide association study); биобанк; метаболические заболевания; неалкогольная жировая болезнь печени; ожирение; сахарный диабет; шкала генетического риска
• ISSN: 1728-8800; 2619-0125
• DOI: 10.15829/1728-8800-2021-3123

The growing prevalence of metabolic disorders creates an increasing demand for novel approaches to their prevention and therapy. Novel genetic diagnostic technologies are developed every year, which makes it possible to identify people who are at the highest genetic risk of diabetes, non-alcoholic fatty liver disease, and metabolic syndrome. Early intervention strategies can be used to prevent metabolic disorders in this group of people. Genetic risk scores (GRSs) are a powerful tool to identify people with a high genetic risk. Millions of genetic variants are analyzed in genome-wide association studies in order to combine them into GRSs. It has become possible to store and process such huge amounts of data with the help of biobanks, where biological samples are stored according to international standards. Genetic studies include more and more people every year that increases the predictive power of GRSs. It has already been demonstrated that the use of GRSs makes future preventive measures more effective. In the near future, GRSs are likely to become part of clinical guidelines so that they can be widely used to identify people at high risk for metabolic syndrome and its components.